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Summary 
Background Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been 
shown to reduce myocardial infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing 
primary percutaneous coronary intervention (PPCI). We investigated whether remote ischaemic conditioning could 
reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months.
Methods We did an international investigator-initiated, prospective, single-blind, randomised controlled trial 
(CONDI-2/ERIC-PPCI) at 33 centres across the UK, Denmark, Spain, and Serbia. Patients (age >18 years) with 
suspected STEMI and who were eligible for PPCI were randomly allocated (1:1, stratified by centre with a permuted 
block method) to receive standard treatment (including a sham simulated remote ischaemic conditioning intervention 
at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the 
arm through four cycles of 5-min inflation and 5-min deflation of an automated cuff device) before PPCI. Investigators 
responsible for data collection and outcome assessment were masked to treatment allocation. The primary combined 
endpoint was cardiac death or hospitalisation for heart failure at 12 months in the intention-to-treat population. This 
trial is registered with ClinicalTrials.gov (NCT02342522) and is completed.
Findings Between Nov 6, 2013, and March 31, 2018, 5401 patients were randomly allocated to either the control group 
(n=2701) or the remote ischaemic conditioning group (n=2700). After exclusion of patients upon hospital arrival or loss to 
follow-up, 2569 patients in the control group and 2546 in the intervention group were included in the intention-to-treat 
analysis. At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart 
failure (the primary endpoint) were 220 (8·6%) patients in the control group and 239 (9·4%) in the remote ischaemic 
conditioning group (hazard ratio 1·10 [95% CI 0·91–1·32], p=0·32 for intervention versus control). No important 
unexpected adverse events or side effects of remote ischaemic conditioning were observed.
Interpretation Remote ischaemic conditioning does not improve clinical outcomes (cardiac death or hospitalisation 
for heart failure) at 12 months in patients with STEMI undergoing PPCI.
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Introduction
Despite timely reperfusion with primary percutaneous 
coronary intervention (PPCI), morbidity and mortality 
following acute ST-elevation myocardial infarction 
(STEMI) remain substantial, and improvements in mor-
tality and survival free of heart failure have plateaued.1,2 
New treatments are needed to reduce myocardial infarct 
size and preserve cardiac function to reduce risk of death 
and prevent onset of heart failure. In this regard, remote 
ischaemic conditioning, in which brief cycles of ischaemia 
and reperfusion are applied to an organ or tissue 
(including a limb) away from the heart, has been shown 
to reduce myocardial infarct size in animal models.2,3
In the clinical setting, the cardioprotective remote 
ischaemic conditioning stimulus can be applied using 
serial inflations and deflations of a pneumatic cuff placed 
on the upper arm or thigh to induce brief cycles of 
ischaemia and reperfusion.4 In most clinical studies in 
patients with STEMI, remote ischaemic conditioning has 
increased myocardial salvage and reduced myocardial 
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infarct size by 20–30% when applied before or during 
reperfusion.5–12 In addition, two follow-up studies and 
a prospective single-centre study have suggested that 
remote ischaemic conditioning might also improve 
clinical outcomes in patients with STEMI undergoing 
PPCI.13–15 However, a large, sufficiently powered, pro-
spectively designed multicentre clinical outcome study 
has not yet been done. Therefore, in the CONDI-2/
ERIC-PPCI trial, we investigated the effect of remote 
ischaemic conditioning applied as an adjunct to PPCI on 
rates of cardiac death or hospitalisation for heart failure at 
12 months in patients with STEMI. In this study, we 
combined the CONDI-2 and ERIC-PPCI trials and 
harmonised the protocols to increase sample size and 
ensure the study was sufficiently powered to detect an 
effect of remote ischaemic conditioning on clinical 
outcomes in patients with STEMI treated by PPCI.
Methods 
Study design
We did an international, multicentre, single-blind, 
randomised controlled trial at 26 centres in the UK (the 
ERIC-PPCI component study), and at four hospitals in 
Denmark, two hospitals in Spain, and one hospital in 
Serbia (the CONDI-2 component study). The CONDI-2/
ERIC-PPCI study received ethical approval from regional 
and national health service research ethics committees 
and was conducted in accordance with the principles 
of good clinical practice. In the CONDI-2 component 
study, all participants provided written informed consent 
before randomisation. In the ERIC-PPCI component 
study, all patients provided initial verbal assent before 
randomisation, which was followed by written informed 
consent. The London School of Hygiene & Tropical 
Medicine Clinical Trials Unit (London, UK) coordinated 
the trial in collaboration with the Cardiology Trial Unit 
and Department of Clinical Epidemiology of Aarhus 
University Hospital (Aarhus, Denmark). Details of the 
trial design have been reported previously,16 and a copy 
of the protocol is available in appendix 2.
Participants
Patients with chest pain and suspected ST-segment 
elevation on electrocardiogram (ECG) were screened for 
possible inclusion. Patients were included if they were 
older than 18 years of age, had ST-segment elevation on 
Research in context
Evidence before this study
To improve clinical outcomes in patients with ST-elevation 
myocardial infarction (STEMI) treated by primary percutaneous 
coronary intervention (PPCI), new treatments are needed to 
protect the heart against acute ischaemia–reperfusion injury 
and thus reduce myocardial infarct size and prevent heart 
failure. Remote ischaemic conditioning with transient 
ischaemia and reperfusion of the arm or leg as an adjunct to 
PPCI has been shown in several small randomised controlled 
trials to reduce myocardial infarct size and increase myocardial 
salvage in patients with STEMI when compared with use of 
PPCI alone. However, whether remote ischaemic conditioning 
can improve clinical outcomes such as mortality and heart 
failure has not been confirmed. A PubMed search undertaken 
up to the start date of the trial (July 14, 2013) using the terms 
“remote ischemic conditioning; acute myocardial infarction; 
mortality; and heart failure” revealed no randomised controlled 
trials investigating the effect of remote ischaemic conditioning 
on clinical outcomes in patients with STEMI treated by PPCI.
Added value of this study
In this large, sufficiently powered, multicentre, randomised 
controlled trial of 5401 patients with STEMI, we investigated 
whether remote ischaemic conditioning applied as an adjunct 
to PPCI could reduce the incidence of cardiac death or 
hospitalisation for heart failure within 12 months post-PPCI, 
when compared with PPCI alone. Our findings showed that 
remote ischaemic conditioning did not improve clinical 
outcomes in terms of cardiac death or hospitalisation for heart 
failure at this timepoint. Furthermore, no improvements in any 
of the secondary endpoints were found, including major adverse 
cardiovascular and cerebral events and myocardial infarct size 
evaluated by troponin T release. Furthermore, no effects of the 
intervention versus the control were seen among prespecified 
subgroup analyses by age, presence of diabetes, pre-PPCI 
coronary flow, ischaemia time, or infarct location.
Implications of all the available evidence
The CONDI-2/ERIC-PPCI trial has provided definitive evidence 
that remote ischaemic conditioning offers no benefits on either 
myocardial infarct size or clinical outcomes at 12 months in 
patients with STEMI treated with PPCI. Two follow-up 
randomised controlled trials and a prospective single-centre 
randomised controlled trial, published since the 
commencement of our trial, had suggested that remote 
ischaemic conditioning might improve clinical outcomes in 
patients with STEMI undergoing PPCI. The two follow-up trials 
were not prospectively designed or powered to detect a 
difference in clinical outcomes with remote ischaemic 
conditioning. The prospective single-centre trial might not 
have been sufficiently powered, and it had an extended 
follow-up period. Until now, remote ischaemic conditioning 
had been the most promising potential cardioprotective 
strategy for improving clinical outcomes following STEMI. 
Therefore, identification of novel cardioprotective targets and 
discovery of innovative approaches to cardioprotection are 
needed to improve clinical outcomes in patients with STEMI 
treated by PPCI. Such approaches might include combination 
multitarget therapy. Remote ischaemic conditioning might still 
be beneficial in other clinical settings of acute 
ischaemia–reperfusion injury, including renal transplantation, 
acute kidney injury, and stroke.
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ECG, and were eligible for PPCI. Exclusion criteria were 
previous coronary artery bypass graft surgery, myocardial 
infarct within the previous 30 days, left bundle branch 
block on ECG, treatment with therapeutic hypothermia, 
conditions precluding use of remote ischaemic 
conditioning (paresis of upper limb, or presence of an 
arteriovenous shunt), and life expectancy of less than 
1 year due to a non-cardiac pathology.
Randomisation and masking
In both trials, patients were randomly allocated (1:1) to a 
remote ischaemic conditioning group or a control group 
by a designated study team member who was unmasked 
to treatment allocation. For ERIC-PPCI, randomisation 
was done via a secure website, Sealed Envelope (London, 
UK), and was stratified by centre with use of random 
permuted blocks  (block sizes of 4 or 6). For CONDI-2, 
randomisation was done through a web-based clinical 
trial support system accessible 24 h a day (TrialPartner, 
Aarhus, Denmark) and stratified by centre using random 
permuted blocks (block sizes of 4, 6, or 8). In both 
trials, access to the randomisation website and list were 
strictly controlled at each site and limited to unmasked 
study team members. Study team members collecting 
the data and assessing outcomes were masked to the 
treatment allocation.
Procedures
An automated AutoRIC cuff device (CellAegis Devices, 
Toronto, ON, Canada) was used to deliver the remote 
ischaemic conditioning protocol, which comprised 
four alternating cycles of cuff inflation for 5 min to 
200 mm Hg and deflation for 5 min. At the UK sites, the 
control group received a sham simulated remote 
ischaemic conditioning intervention. At the sites in 
Denmark, Spain, and Serbia, the control group received 
standard therapy. The remote ischaemic conditioning 
and control protocols were implemented before PPCI and 
did not delay the onset of PPCI. Where ambulance transit 
times allowed, remote ischaemic conditioning was 
administered in the ambulance (in Denmark and Spain). 
Where ambulance transit times were shorter, remote 
ischaemic conditioning was delivered immediately upon 
arrival at the PPCI centre (in Serbia and the UK).
Before PPCI, patients were treated with 300 mg 
aspirin orally or intravenously, 600 mg clopidogrel or 
180 mg ticagrelor orally, and standard weight-adjusted 
heparin intravenously. The PPCI procedure followed 
guideline recommendations;17 ad hoc thrombectomy 
and administration of glycoprotein IIb/IIIa inhibitors, 
bivalirudin, or cangrelor were per operator discretion.
Outcomes
The primary combined endpoint was cardiac death 
or hospitalisation for heart failure at 12 months post-
randomisation in the intention-to-treat population. 
Hospitalisation for heart failure included heart failure 
both during the index hospitalisation and during 
rehospitalisation for heart failure. Hospitalisation was 
defined as treatment occurring during a hospital 
admission. Heart failure was judged to be present on the 
basis of at least one of the following symptoms and 
signs: new or worsening dyspnoea, orthopnoea, or 
paroxysmal nocturnal dyspnoea; increasing fatigue or 
worsening exercise tolerance; ejection fraction less than 
45% on echocardiography; new pulmonary oedema seen 
on chest x-ray in the absence of a non-cardiac cause; 
crepitations believed to be due to pulmonary oedema; 
and use of loop diuretics to treat presumed pulmonary 
congestion.18 A blinded independent event validation 
committee reviewed all events according to standard 
operational procedures. Hospitalisation for heart failure 
was defined as an event that met the standard criteria18 
(appendix 1 p 20).
Prespecified secondary endpoints, analysed in the 
intention-to-treat population, included combined cardiac 
death or hospitalisation for heart failure at 30 days; cardiac 
death and hospitalisation for heart failure (as individual 
endpoints) at 30 days and 12 months; major cardiovascular 
and cerebral adverse events (comprising all-cause death, 
reinfarction, repeat coronary revascularisation, and stroke; 
appendix 1 p 20) at 30 days and 12 months; incidence of 
implantable cardioverter-defibrillator insertion within 
12 months; repeated episodes of hospitalisation for heart 
failure within 12 months; and myocardial infarct size 
(quantified by area under the curve [AUC] for high-
sensitivity troponin T measured at 0–48 h after PPCI) in a 
subset of patients.
Statistical analysis
The primary outcome event rate was originally predicted 
to be 11·0% at 12 months. To show a 25% relative 
reduction in the remote ischaemic conditioning group 
(from 11·0% to 8·25%) with 80% power and 5% signifi-
cance would have required 4300 patients (2000 patients 
in ERIC-PPCI and 2300 in CONDI-2), allowing for 
15% attrition. A blinded review of accruing data revealed 
that the estimated event rate was lower than anticipated 
and the sample size was, therefore, increased to 
5400 patients (2800 patients in ERIC-PPCI and 2600 in 
CONDI-2).
The primary and secondary time-to-event outcomes 
were compared between the remote ischaemic 
conditioning and control groups with use of a Cox 
regression model stratified by the two component 
studies on an intention-to-treat basis, and presented 
with Kaplan-Meier curves. To account for recurrent 
hospitalisation for heart failure and competing mortality 
risk, a negative binomial model was used to compare 
the total number of outcomes experienced by the 
two groups up to 12 months after randomisation. The 
proportion of patients with an implantable cardioverter-
defibrillator, biventricular pacemaker, or single-chamber 
or dual-chamber pacemaker at 12 months was compared 
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using a generalised linear model for a binary outcome 
with a log link.
Prespecified analyses by subgroup (age [<55 years, 
55 to <65 years, 65 to <75 years, or ≥75 years], diabetic 
status, infarct location [left anterior descending artery or 
other], pre-angioplasty TIMI flow grade [0–1 or 2–3], and 
time elapsed between first medical contact and PPCI 
[<90 min, 90 to <120 min, or 120 to 720 min]) were done 
on the primary outcome. The subgroups were analysed 
by including an interaction term between treatment 
group and subgroup in the Cox regression model.
Troponin T values were converted into a 48-h AUC 
summary measure for analysis, using multiple impu-
tation by chained equations to account for missing data. 
As the distribution of the outcome variable was highly 
skewed, a log transformation was done. Differences were 
analysed by use of a linear regression model with the 
treatment effect presented as a ratio of the geometric 
means.
We also did a per-protocol analysis of all primary and 
secondary outcomes limited to patients who had a 
confirmed STEMI, received the full intervention as 
specified in the protocol, and had a completed PPCI.
Results were considered statistically significant if the 
two-sided p value was less than 0·05. Full details of the 
statistical methods are provided in the protocol and 
statistical analysis plan, which are available in appendix 2.
The CONDI-2/ERIC-PPCI trial is registered at 
ClinicalTrials.gov (number NCT02342522) and is a 
planned prespecified collaboration between the CONDI-2 
and ERIC-PPCI studies (for further details see appendix 1 
pp 20–21).
Role of the funding source
The sponsor had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The co-corresponding authors had full access 
to all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Nov 6, 2013, and March 31, 2018, 5401 patients 
were randomly allocated: 2701 to the control group and 
2700 to the remote ischaemic conditioning group. 
5115 patients (2569 in the control group and 2546 in the 
remote ischaemic conditioning group) were included in 
the intention-to-treat analysis (figure 1). The treatment 
groups were well balanced with respect to both patient 
baseline characteristics and PPCI details for the intention-
to-treat analysis (table 1). The intervention was completed 
according to protocol for 2205 participants in the control 
group and 2008 in the remote ischaemic conditioning 
group, and the results were included in the per-protocol 
analysis. Reasons for incomplete interventions are 
provided in figure 1.
There was no evidence of difference between the con-
trol group (8·6% [n=220]) and the remote ischaemic 
conditioning group (9·4% [n=239]) with respect to the 
combined primary end point of cardiac death or hos-
pitalisation for heart failure at 12 months (hazard ratio 
[HR] 1·10; 95% CI 0·91–1·32; p=0·32; table 2, figure 2). 
Similarly, the control and remote ischaemic conditioning 
groups did not differ with regard to the individual 
components of cardiac death or hospitali sation for heart 
failure at 12 months (table 2, figure 2). The primary and 
secondary outcomes in CONDI-2 and ERIC-PPCI were 
similar, with no effect of remote ischaemic conditioning 
seen in either study (appendix 1 pp 25–30, 32–37).
Prespecified subgroup analyses showed no difference 
in the effect of remote ischaemic conditioning on the 
primary outcome by age, presence of diabetes, pre-PPCI 
TIMI flow grade, time from first medical contact to PPCI, 
or infarct location (figure 3). The results of the per-
protocol analysis were very similar to those of the 
Figure 1: Trial profile
PPCI=primary percutaneous coronary intervention. STEMI=ST-elevation myocardial infarction. *Full screening log 
data were not available as not all sites were able to collect screening logs given the emergency context of patient 
enrolment and randomisation. †ERIC-PPCI had approval from the UK Confidentiality Group to collect data on 
patients who died before consent could be obtained (20 patients in the control group and 22 patients in the 
remote ischaemic conditioning group); thus, these patients were included in subsequent analyses. 
5401 patients randomly allocated*
2701 allocated to control group 2700 allocated to receive remote ischaemic 
 conditioning
34 excluded on arrival at hospital
 13 refused to give written consent after 
  verbally consenting
 10 randomised in error
 5 mental impairment
 4 language barrier
 2 died before written consent obtained
29 excluded on arrival at hospital
 13 refused written consent after verbally 
  assenting
 7 randomised in error
 2 mental impairment
 5 language barrier
 2 died before written consent obtained
2667 included on arrival at hospital 2671 included on arrival at hospital
98 lost to follow-up†
 69 patient refused consent for follow-up
 2 patient withdrew
 3 language barrier
 7 patient lacked capacity to consent
 13 patient discharged before consenting
 2 randomised in error
 2 clinical decision to withdraw
125 lost to follow-up†
 84 patient refused consent for follow-up
 3 patient withdrew
 6 language barrier
 6 patient lacked capacity to consent
 19 patient discharged before consenting
 2 randomised in error
 5 clinical decision to withdraw
2569 included in intention-to-treat analysis 2546 included in intention-to-treat analysis 
2205 included in per-protocol analysis 2008 included in per-protocol analysis
364 excluded from per-protocol analysis
 219 no STEMI
 86 no PPCI done
 59 did not receive sham remote 
  ischaemic conditioning as specified 
  in protocol
538 excluded from per-protocol analysis
 210 no STEMI
 80 no PPCI done
 248 did not receive remote ischaemic 
  conditioning as specified 
  in protocol
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intention-to-treat analysis for the primary outcome 
(appendix 1 p 24), with the primary combined endpoint 
within 12 months occurring in 179 (9·0%) participants 
in the remote ischaemic conditioning group versus 
178 (8·1%) in the control group (HR 1·11 [95% CI 
0·90–1·36], p=0·35).
With respect to major cardiovascular and cerebral 
adverse events within 12 months of follow-up, no 
Control group 
(n=2569)
Remote ischaemic 
conditioning group 
(n=2546)
Baseline characteristics
Age, years 63·1 (12·2) 63·9 (12·1)
Sex
Female 576/2569 (22·4%) 611/2546 (24·0%)
Male 1993/2569 (77·6%) 1935/2546 (76·0%)
Body-mass index (kg/m²) 27·5 (4·7) 27·5 (4·9)
Current smoker 1015/2483 (40·9%) 993/2449 (40·5%)
Comorbidities
Hypertension 1020/2544 (40·1%) 1100/2518 (43·7%)
Previous acute 
myocardial infarction
253/2553 (9·9%) 265/2530 (10·5%)
Hypercholesterolaemia 682/2503 (27·2%) 696/2490 (28%)
Medically treated 
diabetes
265/2557 (10·4%) 302/2534 (11·9%)
Family history of 
ischaemic heart disease
819/2387 (34·3%) 853/2337 (36·5%)
Medications at admission for PPCI
Sulfonylurea 62/2519 (2·5%) 61/2496 (2·4%)
Metformin 196/2518 (7·8%) 221/2499 (8·8%)
Insulin 74/2548 (2·9%) 81/2533 (3·2%)
Clopidogrel 85/2548 (3·3%) 98/2528 (3·9%)
Ticagrelor 52/2549 (2·0%) 62/2527 (2·5%)
Prasugrel 4/2546 (0·2%) 3/2528 (0·1%)
Statins 652/2547 (25·6%) 665/2526 (26·3%)
Aspirin 456/2548 (17·9%) 485/2528 (19·2%)
β blockers 384/2539 (15·1%) 407/2525 (16·1%)
Angiotensin-converting 
enzyme inhibitors or 
angiotensin receptor 
blockers
456/2541 (17·9%) 466/2525 (18·5%)
Blood pressure at randomisation, mm Hg
Systolic 131 (24) 131 (24)
Diastolic 77 (15) 76 (15)
Killip class at randomisation
I 2462/2568 (95·9%) 2435/2546 (95·6%)
II 75/2568 (2·9%) 75/2546 (2·9%)
III 14/2568 (0·5%) 11/2546 (0·4%)
IV (including 
cardiogenic shock)
17/2568 (0·7%) 25/2546 (1·0%)
Procedural details
Number of complete cycles of remote ischaemic conditioning 
administered
1 NA 37/2246 (1·6%)
2 NA 40/2246 (1·8%)
3 NA 142/2246 (6·3%)
4 NA 2027/2246 (90·2%)
TIMI flow grade at admission
0 1513/2227 (67·9%) 1478/2203 (67·1%)
1 154/2227 (6·9%) 145/2203 (6·6%)
2 218/2227 (9·8%) 225/2203 (10·2%)
3 342/2227 (15·4%) 355/2203 (16·1%)
(Table 1 continues in next column)
Control group 
(n=2569)
Remote ischaemic 
conditioning group 
(n=2546)
(Continued from previous column)
Symptom to balloon time, 
min
177 (128–279) 178 (130–278)
First medical contact to 
balloon time, min
102 (82–126) 103 (83–128)
Infarct-related coronary artery
Left anterior descending 974/2258 (43·1%) 911/2226 (40·9%)
Circumflex 297/2258 (13·2%) 298/2226 (13·4%)
Right coronary 985/2258 (43·6%) 1014/2226 (45·6%)
Other 2/2258 (0·1%) 3/2226 (0·1%)
Number of vessels with clinically significant disease
0 1/2258 (<0·1%) 2/2227 (0·1%)
1 1314/2258 (58·2%) 1274/2227 (57·2%)
2 659/2258 (29·2%) 641/2227 (28·8%)
3 284/2258 (12·6%) 310/2227 (13·9%)
Stenting of culprit lesion 
by PPCI
2104/2258 (93·2%) 2080/2226 (93·4%)
Aspiration thrombectomy 560/2242 (24·8%) 553/2209 (24·8%)
Supplementary staged 
PPCI
291/2258 (12·9%) 261/2227 (11·7%)
Supplementary staged 
coronary artery bypass 
grafting
52/2258 (2·3%) 62/2227 (2·8%)
TIMI flow grade after procedure
0 27/2223 (1·2%) 26/2200 (1·2%)
1 20/2223 (0·9%) 9/2200 (0·4%)
2 112/2223 (5·0%) 86/2200 (3·9%)
3 2064/2223 (92·8%) 2079/2200 (94·5%)
Medications given in relation to PPCI
Opioids* 549/1054 (52·1%) 522/1040 (50·2%)
Heparin 1904/2255 (84·4%) 1893/2224 (85·1%)
Aspirin 2147/2255 (95·2%) 2129/2221 (95·9%)
Clopidogrel 610/2256 (27·0%) 573/2226 (25·7%)
Ticagrelor 1551/2257 (68·7%) 1554/2227 (69·8%)
Prasugrel 103/2256 (4·6%) 97/2226 (4·4%)
Nitrates 1758/2222 (79·1%) 1693/2185 (77·5%)
Glycoprotein IIb/IIIa 
inhibitor
450/2250 (20·0%) 404/2223 (18·2%)
Bivalirudin 505/2250 (22·4%) 489/2224 (22·0%)
Cangrelor* 134/1088 (12·3%) 127/1085 (11·7%)
Data are n/N (%), mean (SD), or median (IQR). Numbers of missing data are 
provided in appendix 1 (pp 37–39). PPCI=primary percutaneous coronary 
intervention. NA=not applicable. *Data collected only in the CONDI-2 trial.
Table 1: Baseline characteristics and procedural details for the 
intention-to-treat population
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difference was observed between the remote ischaemic 
conditioning group and the control group, for either 
the combined outcome or the individual components 
(table 2).
No differences between the control and remote 
ischaemic conditions group were observed with regard to 
cardiac death or hospitalisation for heart failure (both 
combined and individually) within 30 days, major cardio-
vascular and cerebral adverse events (or the individual 
components of this outcome) after 30 days, or incidence 
of implantable cardioverter-defibrillator implantation 
within 12 months (table 2). Numbers of repeat episodes 
of hospitalisation for heart failure, or repeat episodes 
of hospitalisation for heart failure plus cardiac death 
were also similar between groups (table 2). Secondary 
endpoints were very similar between the CONDI-2 and 
ERIC-PPCI trials (appendix 1 pp 45, 57).
The AUC for high-sensitivity troponin T did not differ 
between the control group (median 91·9 ng × h/mL 
[IQR 37·6–185·6], n=1330) and the remote ischaemic 
conditioning group (110·3 ng × h/mL [48·0–218·5], 
n=1332; ratio of means 1·05 [95% CI 0·92–1·18], p=0·48; 
appendix 1 p 66).
No unexpected adverse events related to the trial 
treatment were reported. Skin petechiae and transient 
pain or paraesthesia were considered expected adverse 
events of remote ischaemic conditioning. In the remote 
ischaemic conditioning group, skin petechiae were 
reported for 72 (2·8%) patients and transient pain or 
paraesthesia was reported for 147 (5·8%) patients. There 
were no withdrawals due to adverse events.
Discussion
In this large, appropriately powered, prospective, 
international, multicentre trial, we found no clinically 
meaningful beneficial effects of remote ischaemic 
conditioning administered as an adjunct to PPCI on 
clinical outcomes (cardiac death or hospitalisation for 
heart failure) at 12 months in patients with STEMI when 
compared with PPCI alone. Furthermore, remote 
ischaemic conditioning had no effect on major secondary 
endpoints, including myocardial infarct size assessed by 
cardiac biomarkers.
These findings are in direct contrast to previously 
published clinical studies of remote ischaemic 
conditioning in patients with STEMI that reported 
increased myocardial salvage (on nuclear myocardial 
perfusion imaging and cardiac MRI) and reductions in 
myocardial infarct size (assessed by cardiac biomarkers 
and cardiac imaging),5–12 although not all studies have 
been positive for these endpoints.12 In our initial proof-of-
concept CONDI-1 trial, no statistically significant 
reduction in myocardial infarct size (assessed by cardiac 
biomarkers) was observed despite an increase in myo-
cardial salvage.5 Measurements of cardiac biomarkers 
might not be a sufficiently sensitive marker for detecting 
reductions in myocardial infarct size with cardioprotective 
therapies, and myocardial salvage might be a more 
sensitive marker to assess cardioprotection. In our cardiac 
biomarker analysis of a subset of 2662 patients, we found 
no effect of remote ischaemic conditioning on myocardial 
infarct size assessed by troponin T release, confirming no 
biological effects of remote ischaemic conditioning, a 
finding which is consistent with the observed absence of 
effect on clinical outcomes at 12 months. The lack of 
effect observed in our study raises the possibility that 
previously published, smaller studies, which used similar 
remote ischaemic conditioning protocols, were subject to 
type 1 errors.5–12
Outcomes* Treatment effect† 
(95% CI)
p value
Control group 
(n=2569)
Remote 
ischaemic 
conditioning 
group (n=2546)
Time-to-event outcomes
Combined cardiac death or 
hospitalisation for heart failure within 
12 months (primary outcome)
220 (8·6%) 239 (9·4%) 1·10 (0·91–1·32) 0·32
Cardiac death within 12 months 69 (2·7%) 77 (3·1%) 1·13 (0·82–1·56) 0·46
Hospitalisation for heart failure 
within 12 months
182 (7·1%) 192 (7·6%) 1·06 (0·87–1·30) 0·55
Major cardiovascular and cerebral 
adverse events‡ within 12 months
197 (7·8%) 212 (8·4%) 1·09 (0·90–1·32) 0·38
All-cause death within 12 months 100 (3·9%) 122 (4·8%) 1·24 (0·95–1·61) 0·11
Reinfarction within 12 months 43 (1·7%) 38 (1·5%) 0·89 (0·58–1·38) 0·61
Unplanned revascularisation within 
12 months
61 (2·4%) 61 (2·5%) 1·02 (0·71–1·45) 0·93
Stroke within 12 months 21 (0·8%) 23 (0·9%) 1·11 (0·61–2·00) 0·73
Combined hospitalisation for heart 
failure or cardiac death within 30 days
185 (7·2%) 204 (8·0%) 1·11 (0·91–1·36) 0·29
Cardiac death within 30 days 47 (1·8%) 59 (2·3%) 1·27 (0·87–1·86) 0·22
Hospitalisation for heart failure 
within 30 days
162 (6·3%) 171 (6·8%) 1·06 (0·86–1·32) 0·57
Major cardiovascular and cerebral 
adverse events‡ within 30 days
97 (3·8%) 109 (4·3%) 1·14 (0·87–1·50) 0·35
All-cause death within 30 days 52 (2·0%) 63 (2·5%) 1·23 (0·85–1·77) 0·27
Reinfarction within 30 days 21 (0·8%) 19 (0·8%) 0·92 (0·49–1·70) 0·78
Unplanned revascularisation within 
30 days
29 (1·1%) 29 (1·2%) 1·02 (0·61–1·70) 0·95
Stroke within 30 days 7 (0·3%) 10 (0·4%) 1·44 (0·55–3·80) 0·46
Implantable cardioverter-defibrillator 
implantation within 12 months
28 (1·1%) 37 (1·5%) 1·34 (0·82–2·18) 0·24
Event frequency outcomes
Number of repeat episodes of 
hospitalisation for heart failure within 
12 months
0·09 (0·36) 0·09 (0·34) 1·00 (0·81–1·24) 1·00
Number of repeat episodes of 
hospitalisation for heart failure or 
cardiac death within 12 months
0·11 (0·43) 0·12 (0·41) 1·03 (0·85–1·25) 0·77
*Data are Kaplan-Meier estimates of the n (%) of patients with the outcome at the specified timepoint (for time-to-event 
outcomes), or mean (SD; for event frequency outcomes). †Data are hazard ratios (for time-to-event outcomes) or ratio 
of means (for event frequency outcomes), for treatment group versus control group. ‡Composite of all-cause death, 
reinfarction, unplanned revascularisation, and stroke. 
Table 2: Primary and secondary outcomes in the intention-to-treat population
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Although myocardial infarct size is a known inde-
pendent determinant of clinical outcomes post-PPCI in 
patients with STEMI, it is unclear whether a reduction in 
myocardial infarct size by a cardioprotective inter vention 
applied as an adjunct to PPCI can be translated into 
improved clinical outcomes. The RIC-STEMI trial by 
Gaspar and colleagues15 also showed no reduction in 
myocardial infarct size (based on 48 h troponin I AUC), 
but still found improved clinical outcomes with remote 
ischaemic conditioning in terms of fewer cardiac deaths 
or hospitalisations for heart failure after a median follow-
up time of 2·1 years (HR 0·35 [95% CI 0·15–0·78]). The 
unexpected and discordant effects of remote ischaemic 
conditioning on myocardial infarct size and clinical 
outcomes in the RIC-STEMI trial15 might have been due 
to a type 1 error, as only 516 patients with STEMI 
were randomly allocated, and the numbers of cardiac 
mortality events (three [1%] in the remote ischaemic 
conditioning group vs 11 [5%] in the control group) and 
hospitalisation for heart failure events (eight [3%] in the 
remote ischaemic conditioning group vs 17 [8%] in the 
control group) were small. An alternative explanation 
could be that the primary effect of remote ischaemic 
conditioning was on post-STEMI left ventricular 
remodelling rather than acute myocardial infarct size—
although this mechanism would contradict experimental 
animal studies, which have clearly shown a beneficial 
effect of remote ischaemic conditioning on reducing 
acute myocardial infarct size. Notably, a clinical study 
investigating the cardioprotective effects of ischaemic 
postconditioning in patients with STEMI treated by PPCI 
showed no effect on myocardial infarct size, but still 
found reduced severity of adverse left ventricular 
remodelling at 1 year of follow-up, especially in patients 
with microvascular obstruction.19
Follow-up (median 3·8 years) of participants in the 
initial CONDI-1 trial5 (n=333 patients with STEMI) showed 
that increased myocardial salvage with remote ischaemic 
conditioning was associated with reduced frequencies 
of major cardiovascular and cerebral adverse events 
(17 [13·5%] patients) compared with the control group 
(32 [25·6%] patients).13 The LIPSIA CONDITIONING 
trial10 (n=696 patients with STEMI) showed improved myo-
cardial salvage in patients who received PPCI combined 
with remote ischaemic conditioning and ischaemic 
postconditioning compared with either the control group 
(patients who received PPCI alone) or patients receiving 
ischaemic postconditioning with PPCI. Follow-up of 
LIPSIA CONDITIONING trial participants at a median of 
3·6 years after the index event also revealed that major 
adverse cardiac events (cardiac death, reinfarction, and 
Figure 2: 12-month cumulative incidence of combined cardiac death or 
hospitalisation for heart failure (A), cardiac death (B), and hospitalisation 
for heart failure (C) in the intention-to-treat population
HR=hazard ratio.
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new congestive heart failure) were reduced in the group 
that received combined remote ischaemic conditioning 
and ischaemic postconditioning (23 [10·2%] patients) 
compared with the control group (37 [16·9%] patients)—
an effect that was mainly driven by a reduced rate of heart 
failure.14 However, these studies were not prospectively 
designed or powered to assess clinical outcomes of remote 
ischaemic conditioning following STEMI. The present 
study is almost ten-times larger than any previous study 
and was adequately powered to address the efficacy of 
remote ischaemic conditioning on clinical outcomes.
The reasons for the failure of remote ischaemic 
conditioning to reduce myocardial infarct size and 
improve clinical outcomes in our study are not clear. One 
potential reason could relate to the remote ischaemic 
conditioning protocol itself. Although four 5-min cycles 
of upper arm cuff inflations and deflations applied before 
PPCI has been shown to increase the myocardial salvage 
index5 and reduce myocardial infarct size in previous 
clinical studies,11 whether this protocol is the most 
effective cardioprotective intervention in terms of cycle 
numbers and duration is not known. One experimental 
study in mice suggested that two cycles of remote 
ischaemic conditioning were ineffective, whereas 
four cycles of remote ischaemic conditioning reduced 
myocardial infarct size to a similar extent to that achieved 
with six or eight cycles.20 However, such phase 2 dose-
response studies in humans are absent. The RIC-STEMI 
study,15 which showed no reduction in myocardial infarct 
size despite improved clinical outcomes, used a remote 
ischaemic conditioning stimulus comprising three cycles 
of inflation and deflation of a pneumatic cuff placed 
on the thigh, in contrast to our remote ischaemic 
conditioning stimulus that consisted of four cycles of 
inflation and deflation of a pneumatic cuff placed on the 
upper arm. The stimulus used in the RIC-STEMI trial 
might be expected to be more efficacious because of the 
greater ischaemic tissue burden, but this explanation 
would not account for the absence of effect on myo-
cardial infarct size in the RIC-STEMI trial. Furthermore, 
a previous experimental study in mice showed that 
bilateral hindlimb remote ischaemic conditioning was 
no more efficacious at reducing myocardial infarct size 
than was unilateral limb remote ischaemic conditioning.20
The timing of the remote ischaemic conditioning 
protocol in relation to reperfusion by PPCI might also be 
important. Previous clinical studies have shown that 
remote ischaemic conditioning is effective at reducing 
myocardial infarct size when administered before PPCI 
(either in transit to the PPCI centre5 or on arrival at the 
hospital11), during reperfusion by PPCI, and even at 
onset of reperfusion.7 In our study, clinical outcomes did 
not differ on the basis of whether the remote ischaemic 
conditioning protocol was completed during transpor-
tation to the PPCI centre or on admission to hospital, 
where the remote ischaemic conditioning protocol 
was continued during reperfusion in most patients 
(appendix  1 pp 40–41). Furthermore, no differences in 
clinical outcomes were observed whether the full four 
cycles of the remote ischaemic conditioning protocol 
Figure 3: Forest plot for prespecified subgroup analyses of the primary endpoint in the intention-to-treat population
*Kaplan-Meier estimates of the number of patients with hospitalisation for heart failure or cardiac death within 12 months.
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was com pleted before reperfusion or not (appendix 1 
pp 40–41).
Comedications and comorbidities might affect the 
cardioprotective efficacy of remote ischaemic condi-
tioning. In experimental studies, P2Y12 receptor 
antagonists con founded the cardioprotective effects of 
ischaemic con ditioning,21,22 although no evidence for 
remote ischaemic conditioning is available. In our trial, 
the P2Y12 receptor antagonist ticagrelor was admin-
istered to 69·8% of patients receiving remote ischaemic 
conditioning. We found no difference in clinical 
outcomes between the control group and the remote 
ischaemic conditioning group with respect to ticagrelor 
administration (appendix 1 p 41).
Experimental data have shown that age and presence of 
comorbidities, including diabetes, might attenuate the 
cardioprotective effects of ischaemic preconditioning and 
postconditioning.23 Whether these factors affected the 
cardioprotective efficacy of remote ischaemic conditioning 
in our study remains unclear; our prespecified subgroup 
analyses showed no differences in clinical outcomes 
between the control group and the remote ischaemic 
conditioning group with increasing age or presence of 
diabetes (figure 3).
The efficacy of cardioprotective interventions applied at 
reperfusion in patients with STEMI is closely related to 
myocardial infarct size and pre-PPCI TIMI flow, with the 
greatest benefit reported for patients with complete 
occlusion (pre-PPCI TIMI flow ≤1) due to infarcts in the 
left anterior descending artery.5 However, our prespecified 
subgroup analyses showed no differences in clinical 
outcomes according to pre-PPCI TIMI flow and infarct 
location (figure 3).
Remote ischaemic conditioning has shown mixed 
effects on outcomes in other clinical settings including 
cardiac surgery. Three large, prospective, multicentre, 
randomised controlled trials failed to find any beneficial 
effects of remote ischaemic conditioning on post-surgical 
clinical outcomes,24–26 possibly because of the confounding 
effects of propofol anaesthesia. Smaller studies of 
remote ischaemic conditioning in patients with stroke, 
renal transplantation, or undergoing elective PCI have 
suggested potential benefits.27–29 A clinical study in patients 
with STEMI treated by PPCI investigated the effects of 
remote ischaemic conditioning applied daily for 1 month 
(termed chronic remote ischaemic conditioning).30 This 
intervention showed no beneficial effects on post-infarct 
left ventricular remodelling, although it was only started 
on day 3 post-PPCI in that study, which might be too late 
to observe any beneficial effects.
A potential limitation of our study is the short follow-up 
time of 12 months post-STEMI for the primary outcome 
of cardiac death and hospitalisation for heart failure, 
which might have been too short to observe any effect of 
remote ischaemic conditioning on clinical outcomes.
In summary, the findings from our trial provide 
conclusive evidence that remote ischaemic conditioning 
offers no benefits on either myocardial infarct size or 
clinical outcomes at 12 months in patients with STEMI 
treated by PPCI. Unfortunately, remote ischaemic con-
ditioning had been the most promising cardioprotective 
strategy for improving clinical outcomes following STEMI, 
and few other prospective options exist. As such, further 
studies are needed to identify novel cardioprotective tar-
gets and innovative approaches to cardioprotection such 
as combination multitarget therapy.31
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